22 results
DRS/A
EVAX
Evaxion Biotech A/S
25 Nov 20
Draft registration statement (amended)
12:00am
through an abbreviated regulatory pathway.
The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation … to patients, a communication plan to health care practitioners, extensive patient monitoring, or distribution systems and processes that are highly
424B4
EVAX
Evaxion Biotech A/S
5 Feb 21
Prospectus supplement with pricing info
4:53pm
from biosimilars approved through an abbreviated regulatory pathway.
The Patient Protection and Affordable Care Act, as amended by the Health Care … of the product for distribution to patients, a communication plan to health care practitioners, extensive patient monitoring, or distribution systems
F-1/A
EVAX
Evaxion Biotech A/S
19 Jan 21
Registration statement (foreign) (amended)
5:05pm
.
The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or the ACA, includes a subtitle called … include, among other things, a medication guide outlining the risks of the product for distribution to patients, a communication plan to health care
DRS/A
EVAX
Evaxion Biotech A/S
16 Dec 20
Draft registration statement (amended)
12:00am
, as amended by the Health Care and Education Reconciliation Act of 2010, or the ACA, includes a subtitle called the Biologics Price Competition … , a medication guide outlining the risks of the product for distribution to patients, a communication plan to health care practitioners, extensive patient
F-1/A
EVAX
Evaxion Biotech A/S
25 Jan 21
Registration statement (foreign) (amended)
7:01am
biosimilars approved through an abbreviated regulatory pathway.
The Patient Protection and Affordable Care Act, as amended by the Health Care and Education … for distribution to patients, a communication plan to health care practitioners, extensive patient monitoring, or distribution systems and processes
DRS/A
a0bsw5odbjuk
4 Jan 21
Draft registration statement (amended)
12:00am
DRS
9o01abe2
22 Oct 20
Draft registration statement
12:00am
20-F
v0e2i9v
7 Apr 21
Annual report (foreign)
4:31pm
F-1
exk0ahhg7mr
8 Jan 21
Registration statement (foreign)
4:54pm
F-1/A
1v7be1ie238ut9
1 Feb 21
Registration statement (foreign) (amended)
4:56pm
DRS
jz4fu
25 Jun 21
Draft registration statement
12:00am
6-K
EX-99.2
60mvv4
25 Oct 21
Evaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA® (pembrolizumab) in Patients with Melanoma
6:00am
F-1/A
sy7x7q9fzvejbxi 387v
30 Jan 24
Registration statement (foreign) (amended)
3:16pm
F-1
3dbgwoz60dahtgb
12 Jan 24
Registration statement (foreign)
5:17pm
424B4
0je7vgq 07
5 Nov 21
Prospectus supplement with pricing info
4:47pm
F-1/A
a5ji2
3 Nov 21
Registration statement (foreign) (amended)
7:50am
F-1
kclsebfxewynvg
26 Oct 21
Registration statement (foreign)
7:02am